Search

Your search keyword '"Bachelez H"' showing total 894 results
Start Over Author "Bachelez H"
894 results on '"Bachelez H"'

3. Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies.

Author

Bachelez, H., Griffiths, C. E. M., Papp, K. A., Hall, S., Merola, J. F., Feldman, S. R., Khraishi, M., Tan, H., Fallon, L., Cappelleri, J. C., Bushmakin, A. G., and Young, P.

Subjects
*PSORIATIC arthritis, *PATIENT reported outcome measures, *PATIENT safety, *HYPERCOAGULATION disorders
Abstract

This document provides a summary of a study on the use of tofacitinib in patients with psoriasis and a history of psoriatic arthritis (PsA). The study found that tofacitinib, at both 5mg and 10mg doses, resulted in significant improvements in skin disease, itch, joint pain, morning stiffness, and depressive symptoms compared to a placebo. The safety profile of tofacitinib was consistent with previous reports. The study suggests that these findings can inform clinical practice and the scientific community. The limitations of the study include the reliance on patient reports for PsA history. The study was sponsored by Pfizer, and the authors disclosed various conflicts of interest. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. Risk of severe COVID-19 associated with immune-modifying drugs: Data from PsoProtect and Global Rheumatology Alliance registries.

Author

Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, Smith CH., Mahil, S, Schaefer, M, Dand, N, Yiu, Z, Hyrich, K, Strangfeld, A, Yates, M, Carmona, L, Gossec, L, Mateus, E, Lawson-Tovey, S, Wiek, D, Jacobsohn, L, Isnardi, C, Quintana, R, Soriano, E, Wallace, Z, Bhana, S, Gore-Massey, M, Grainger, R, Hausmann, J, Liew, J, Sirotich, E, Mason, K, Tsakok, T, Meynell, F, Coker, B, Vincent, A, Urmston, D, Mcateer, H, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Di Meglio, P, Contreras, C, Choon, S, Capon, F, Torres, T, Naldi, L, Weinman, J, Brown, M, Galloway, J, Norton, S, Lambert, J, Spuls, P, Van Huizen, A, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Langan, S, Sufka, P, Robinson, P, Yazdany, J, Griffiths, C, Barker, J, Machado, P, Smith, C, Mahil SK, Schaefer M, Dand N, Yiu ZZN, Hyrich KL, Strangfeld A, Yates M, Carmona L, Gossec L, Mateus EF, Lawson-Tovey S, Wiek D, Jacobsohn L, Isnardi CA, Quintana R, Soriano ER, Wallace ZS, Bhana S, Gore-Massey M, Grainger R, Hausmann JS, Liew JW, Sirotich E, Mason KJ, Tsakok T, Meynell F, Coker B, Vincent A, Urmston D, McAteer H, Vesty A, Kelly J, Lancelot C, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Di Meglio P, Contreras CR, Choon SE, Capon F, Torres T, Naldi L, Weinman J, Brown MA, Galloway JB, Norton S, Lambert J, Spuls P, Van Huizen AM, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Langan SM, Sufka P, Robinson PC, Yazdany J, Griffiths CEM, Barker JN, Machado PM, and Smith CH.

Published
2022

5. 1616 Cross-comparison of inflammatory skin disease transcriptomics identifies PTEN as a pathogenic disease classifier in cutaneous lupus erythematosus

Author

Aevermann, B.D., primary, Di Domizio, J., additional, Olah, P., additional, Armstrong, J.M., additional, Bachelez, H., additional, Barker, J., additional, Haniffa, M., additional, Julia, V., additional, Juul, K., additional, Krishnaswamy, J., additional, Litman, T., additional, Parsons, I., additional, Sarin, K., additional, Schmuth, M., additional, Sierra, M., additional, Simpson, M., additional, Homey, B., additional, Griffiths, C., additional, Scheuermann, R.H., additional, and Gilliet, M., additional

Published
2023
Full Text
View/download PDF

11. Switchs de biothérapies chez les patients atteints de psoriasis modéré à sévère dans la cohorte française Psobioteq

Author

Curmin, R., primary, Guillo, S., additional, de Rycke, Y., additional, Beylot-Barry, M., additional, Beneton, N., additional, Chosidow, O., additional, Dupuy, A., additional, Joly, P., additional, Jullien, D., additional, Richard, M.A., additional, Viguier, M., additional, Sbidian, E., additional, Paul, C., additional, Bachelez, H., additional, Mahé, E., additional, and Tubach, F., additional

Published
2022
Full Text
View/download PDF

12. Tanorexie et psoriasis sévère

Author

Mahé, E., primary, Curmin, R., additional, Paul, C., additional, Bachelez, H., additional, Sbidian, E., additional, Beylot-Barry, M., additional, Beneton, N., additional, Dupuy, A., additional, Joly, P., additional, Jullien, D., additional, Richard, M.A., additional, Viguier, M., additional, Chosidow, O., additional, and Tubach, F., additional

Published
2022
Full Text
View/download PDF

13. Impact de la voie d’administration du méthotrexate sur son maintien en monothérapie dans le psoriasis cutané : données issues de la cohorte PSOBIOTEQ

Author

Paris, C., primary, Gouillon, L., additional, Curmin, R., additional, De, R.Y., additional, Bachelez, H., additional, Beneton, N., additional, Beylot-Barry, M., additional, Dupuy, A., additional, Joly, P., additional, Mahé, E., additional, Paul, C., additional, Richard, M.A., additional, Sbidian, E., additional, Viguier, M., additional, Chosidow, O., additional, Tubach, F., additional, and Jullien, D., additional

Published
2022
Full Text
View/download PDF

15. Facteurs prédictifs d’une poussée de psoriasis après une infection par le SARS-CoV-2 chez l’enfant

Author

Mahé, E., primary, Zitouni, J., additional, Di Lernia, V., additional, Belloni Fortina, A., additional, Lesiak, A., additional, Brzezinski, P., additional, Topkarci, Z., additional, Murashkin, N., additional, Torres, T., additional, Vidaurri De La Cruz, H., additional, Maruani, A., additional, Chiriac, A., additional, Mallet, S., additional, Kupfer-Bessaguet, I., additional, Sonkoly, E., additional, Bursztejn, A.C., additional, Van Den Reek, J., additional, Epishev, R., additional, Severino Freire, M., additional, Akinde, M., additional, Beauchet, A., additional, Luca, C., additional, Thomas, J., additional, Mcpherson, T., additional, Bachelerie, M., additional, Bourrat, E., additional, Bellissen, A., additional, Zafiriou, E., additional, Leducq, S., additional, Neri, I., additional, Luna, P., additional, Steff, M., additional, Sergeant, M., additional, Mahil, S., additional, Smith, C., additional, Flohr, C., additional, and Bachelez, H., additional

Published
2022
Full Text
View/download PDF

16. COVID-19 et psoriasis de l’enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l’infection sur le psoriasis. Registre Chi-PsoCov

Author

Zitouni, J., primary, Bursztejn, A.C., additional, Belloni Fortina, A., additional, Beauchet, A., additional, Di Lernia, V., additional, Lesiak, A., additional, Thomas, J., additional, Topkarci, Z., additional, Murashkin, N., additional, Brzezinski, P., additional, Torres, T., additional, Chiriac, A., additional, Luca, C., additional, Mcpherson, T., additional, Akinde, M., additional, Maruani, A., additional, Epishev, R., additional, Vidaurri De La Cruz, H., additional, Luna, P., additional, Amy De La Breteque, M., additional, Lasek, A., additional, Bourrat, E., additional, Bachelerie, M., additional, Mallet, S., additional, Steff, M., additional, Bellissen, A., additional, Neri, I., additional, Zafiriou, E., additional, Van Den Reek, J., additional, Sonkoly, E., additional, Kupfer-Bessaguet, I., additional, Leducq, S., additional, Mahil, S., additional, Smith, C., additional, Flohr, C., additional, Bachelez, H., additional, and Mahé, E., additional

Published
2022
Full Text
View/download PDF

18. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Author

Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Choon, S, Naldi, L, Lambert, J, Spuls, P, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Shah, A, Barea, A, Romero-Mate, A, Singapore, A, Paolino, A, Mwale, A, Morales Callaghan, A, Martinez, A, Decrescenzo, A, Pink, A, Jones, A, Sergeant, A, Essex, A, Bewley, A, Makrygeorgou, A, van Huizen, A, Perez-Suarez, B, Farida, B, Clareus, B, Prims, C, Davis, C, Quinlan, C, Maybury, C, Cesar, G, Barclay, C, Greco, C, Brassard, D, Cummings, D, Kolli, D, Descamps, V, Genao, D, Carras, E, Hawryluk, E, Martinez-Garcia, E, Klujszo, E, Dwyer, E, Toni, E, Sonkoly, E, Loayza, E, Dauden, E, Valenzuela, F, Popov, G, King, G, Celine, G, Aparicio, G, Johnston, G, Cardozo, G, Pearson, I, Yanguas, I, Weisman, J, Carolan, J, Hughes, J, Ortiz-Salvador, J, Carrascosa, J, Schwartz, J, Jackson, K, Kerisit, K, Wu, K, Asfour, L, de Graaf, L, Lesort, C, Meuleman, L, Eidsmo, L, Skov, L, Gribben, L, Rustin, M, Velasco, M, Panchal, M, Lakhan, M, Franco, M, Svensson, M, Vandaele, M, Marovt, M, Zargari, O, De Caso, P, Varela, P, Jenkin, P, Phan, C, Hampton, P, Goldsmith, P, Bak, R, Speeckaert, R, Romiti, R, Woolf, R, Mercado-Seda, R, Khatun, R, Ceovic, R, Taberner, R, Cohen, R, Stefanescu, S, Kirk, S, Reeken, S, Ayob, S, Perez-Barrio, S, Piaserico, S, Hoey, S, Torres, T, Talme, T, Desai, T, van Geest, A, King, V, Di Lernia, V, Koreja, Z, Hasab, V, Mahil S. K., Dand N., Mason K. J., Yiu Z. Z. N., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., Rossi M. T., Rivera R., Mahe E., Carugno A., Magnano M., Rech G., Balogh E. A., Feldman S. R., De La Cruz C., Choon S. E., Naldi L., Lambert J., Spuls P., Jullien D., Bachelez H., McMahon D. E., Freeman E. E., Gisondi P., Puig L., Warren R. B., Di Meglio P., Langan S. M., Capon F., Griffiths C. E. M., Barker J. N., Smith C. H., Shah A., Barea A., Romero-Mate A., Singapore A., Paolino A., Mwale A., Morales Callaghan A. M., Martinez A., DeCrescenzo A., Pink A. E., Jones A., Sergeant A., Essex A., Bewley A., Makrygeorgou A., van Huizen A., Perez-Suarez B., Farida B., Clareus B. W., Prims C. T., Davis C., Quinlan C., Maybury C., Cesar G. A., Barclay C., Greco C., Brassard D., Cummings D., Kolli D., Descamps V., Genao D. R., Carras E., Hawryluk E., Martinez-Garcia E., Klujszo E., Dwyer E., Toni E., Sonkoly E., Loayza E., Dauden E., Valenzuela F., Popov G., King G., Celine G., Aparicio G., Johnston G. A., Cardozo G. A., Pearson I., Yanguas I., Weisman J., Carolan J. E., Hughes J., Ortiz-Salvador J. -M., Carrascosa J. -M., Schwartz J. J., Jackson K., Kerisit K. G., Wu K., Asfour L., de Graaf L., Lesort C., Meuleman L., Eidsmo L., Skov L., Gribben L., Rustin M., Velasco M., Panchal M., Lakhan M., Franco M. D., Svensson M. -L., Vandaele M., Marovt M., Zargari O., De Caso P., Varela P., Jenkin P., Phan C., Hampton P., Goldsmith P., Bak R., Speeckaert R., Romiti R., Woolf R., Mercado-Seda R., Khatun R., Ceovic R., Taberner R., Cohen R. W., Stefanescu S., Kirk S., Reeken S., Ayob S., Perez-Barrio S., Piaserico S., Hoey S., Torres T., Talme T., Desai T. V., van Geest A. J., King V., Di Lernia V., Koreja Z., Hasab V. Z., Mahil, S, Dand, N, Mason, K, Yiu, Z, Tsakok, T, Meynell, F, Coker, B, Mcateer, H, Moorhead, L, Mackenzie, T, Rossi, M, Rivera, R, Mahe, E, Carugno, A, Magnano, M, Rech, G, Balogh, E, Feldman, S, De La Cruz, C, Choon, S, Naldi, L, Lambert, J, Spuls, P, Jullien, D, Bachelez, H, Mcmahon, D, Freeman, E, Gisondi, P, Puig, L, Warren, R, Di Meglio, P, Langan, S, Capon, F, Griffiths, C, Barker, J, Smith, C, Shah, A, Barea, A, Romero-Mate, A, Singapore, A, Paolino, A, Mwale, A, Morales Callaghan, A, Martinez, A, Decrescenzo, A, Pink, A, Jones, A, Sergeant, A, Essex, A, Bewley, A, Makrygeorgou, A, van Huizen, A, Perez-Suarez, B, Farida, B, Clareus, B, Prims, C, Davis, C, Quinlan, C, Maybury, C, Cesar, G, Barclay, C, Greco, C, Brassard, D, Cummings, D, Kolli, D, Descamps, V, Genao, D, Carras, E, Hawryluk, E, Martinez-Garcia, E, Klujszo, E, Dwyer, E, Toni, E, Sonkoly, E, Loayza, E, Dauden, E, Valenzuela, F, Popov, G, King, G, Celine, G, Aparicio, G, Johnston, G, Cardozo, G, Pearson, I, Yanguas, I, Weisman, J, Carolan, J, Hughes, J, Ortiz-Salvador, J, Carrascosa, J, Schwartz, J, Jackson, K, Kerisit, K, Wu, K, Asfour, L, de Graaf, L, Lesort, C, Meuleman, L, Eidsmo, L, Skov, L, Gribben, L, Rustin, M, Velasco, M, Panchal, M, Lakhan, M, Franco, M, Svensson, M, Vandaele, M, Marovt, M, Zargari, O, De Caso, P, Varela, P, Jenkin, P, Phan, C, Hampton, P, Goldsmith, P, Bak, R, Speeckaert, R, Romiti, R, Woolf, R, Mercado-Seda, R, Khatun, R, Ceovic, R, Taberner, R, Cohen, R, Stefanescu, S, Kirk, S, Reeken, S, Ayob, S, Perez-Barrio, S, Piaserico, S, Hoey, S, Torres, T, Talme, T, Desai, T, van Geest, A, King, V, Di Lernia, V, Koreja, Z, Hasab, V, Mahil S. K., Dand N., Mason K. J., Yiu Z. Z. N., Tsakok T., Meynell F., Coker B., McAteer H., Moorhead L., Mackenzie T., Rossi M. T., Rivera R., Mahe E., Carugno A., Magnano M., Rech G., Balogh E. A., Feldman S. R., De La Cruz C., Choon S. E., Naldi L., Lambert J., Spuls P., Jullien D., Bachelez H., McMahon D. E., Freeman E. E., Gisondi P., Puig L., Warren R. B., Di Meglio P., Langan S. M., Capon F., Griffiths C. E. M., Barker J. N., Smith C. H., Shah A., Barea A., Romero-Mate A., Singapore A., Paolino A., Mwale A., Morales Callaghan A. M., Martinez A., DeCrescenzo A., Pink A. E., Jones A., Sergeant A., Essex A., Bewley A., Makrygeorgou A., van Huizen A., Perez-Suarez B., Farida B., Clareus B. W., Prims C. T., Davis C., Quinlan C., Maybury C., Cesar G. A., Barclay C., Greco C., Brassard D., Cummings D., Kolli D., Descamps V., Genao D. R., Carras E., Hawryluk E., Martinez-Garcia E., Klujszo E., Dwyer E., Toni E., Sonkoly E., Loayza E., Dauden E., Valenzuela F., Popov G., King G., Celine G., Aparicio G., Johnston G. A., Cardozo G. A., Pearson I., Yanguas I., Weisman J., Carolan J. E., Hughes J., Ortiz-Salvador J. -M., Carrascosa J. -M., Schwartz J. J., Jackson K., Kerisit K. G., Wu K., Asfour L., de Graaf L., Lesort C., Meuleman L., Eidsmo L., Skov L., Gribben L., Rustin M., Velasco M., Panchal M., Lakhan M., Franco M. D., Svensson M. -L., Vandaele M., Marovt M., Zargari O., De Caso P., Varela P., Jenkin P., Phan C., Hampton P., Goldsmith P., Bak R., Speeckaert R., Romiti R., Woolf R., Mercado-Seda R., Khatun R., Ceovic R., Taberner R., Cohen R. W., Stefanescu S., Kirk S., Reeken S., Ayob S., Perez-Barrio S., Piaserico S., Hoey S., Torres T., Talme T., Desai T. V., van Geest A. J., King V., Di Lernia V., Koreja Z., and Hasab V. Z.

Abstract

Background: The multimorbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 (COVID-19), but the data are limited. Objective: Our aim was to characterize the course of COVID-19 in patients with psoriasis and identify factors associated with hospitalization. Methods: Clinicians reported patients with psoriasis with confirmed/suspected COVID-19 via an international registry, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection. Multiple logistic regression was used to assess the association between clinical and/or demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviors. Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% were receiving a nonbiologic, and 10% were not receiving any systemic treatment for psoriasis. In all, 348 patients (93%) were fully recovered from COVID-19, 77 (21%) were hospitalized, and 9 (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted odds ratio [OR] = 1.59 per 10 years; 95% CI = 1.19-2.13), male sex (OR = 2.51; 95% CI = 1.23-5.12), nonwhite ethnicity (OR = 3.15; 95% CI = 1.24-8.03), and comorbid chronic lung disease (OR = 3.87; 95% CI = 1.52-9.83). Hospitalization was more frequent in patients using nonbiologic systemic therapy than in those using biologics (OR = 2.84; 95% CI = 1.31-6.18). No significant differences were found between classes of biologics. Independent patient-reported data (n = 1626 across 48 countries) suggested lower levels of social isolation in individuals receiving nonbiologic systemic therapy than in those receiving biologics (OR = 0.68; 95% CI = 0.50-0.94). Conclusion: In this international case series of patients with moderate-to-severe psoriasis, biologic use was associated with lower risk of COVID-19–related hospitalization than with

Published
2021

23. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).

Author

Zitouni, J., Bursztejn, A.C., Belloni Fortina, A., Beauchet, A., Lernia, V. Di, Lesiak, A., Thomas, J, Topkarci, Z., Murashkin, N., Brzezinski, P., Torres, T., Chiriac, A., Luca, C., McPherson, T., Akinde, M., Maruani, A., Epishev, R., Vidaurri de la Cruz, H., Luna, P.C., Lasek, A., Bourrat, E., Bachelerie, M., Mallet, S., Steff, M., Bellissen, A., Neri, I., Zafiriou, E., Reek, J.M.P.A. van den, Sonkoly, E., Mahil, S.K., Smith, C.H., Flohr, C., Bachelez, H., Mahé, E., Zitouni, J., Bursztejn, A.C., Belloni Fortina, A., Beauchet, A., Lernia, V. Di, Lesiak, A., Thomas, J, Topkarci, Z., Murashkin, N., Brzezinski, P., Torres, T., Chiriac, A., Luca, C., McPherson, T., Akinde, M., Maruani, A., Epishev, R., Vidaurri de la Cruz, H., Luna, P.C., Lasek, A., Bourrat, E., Bachelerie, M., Mallet, S., Steff, M., Bellissen, A., Neri, I., Zafiriou, E., Reek, J.M.P.A. van den, Sonkoly, E., Mahil, S.K., Smith, C.H., Flohr, C., Bachelez, H., and Mahé, E.

Abstract

01 november 2022, Item does not contain fulltext, BACKGROUND: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a kno

Published
2022

32. Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.

Author

Bechman, K, primary, Cook, ES, additional, Dand, N, additional, Yiu, ZZN, additional, Tsakok, T, additional, Meynell, F, additional, Coker, B, additional, Vincent, A, additional, Bachelez, H, additional, Barbosa, I, additional, Brown, MA, additional, Capon, F, additional, Contreras, CR, additional, De La Cruz, C, additional, Di Meglio, P, additional, Gisondi, P, additional, Jullien, D, additional, Kelly, J, additional, Lambert, J, additional, Lancelot, C, additional, Langan, SM, additional, Mason, KJ, additional, McAteer, H, additional, Moorhead, L, additional, Naldi, L, additional, Norton, S, additional, Puig, L, additional, Spuls, P, additional, Torres, T, additional, Urmston, D, additional, Vesty, A, additional, Warren, RB, additional, Waweru, H, additional, Weinman, J, additional, Griffiths, CEM, additional, Barker, JN, additional, Smith, CH, additional, Galloway, JB, additional, and Mahil, SK, additional

Published
2022
Full Text
View/download PDF

34. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

Author

Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Arenberger, P., Bachelez, H., Barker, J., Dauden, E., de Jong, E. M., Feist, E., Jacobs, A., Jobling, R., Kemény, L., Maccarone, M., Mrowietz, U., Papp, K. A., Paul, C., Reich, K., Rosumeck, S., Talme, T., Thio, H. B., van de Kerkhof, P., Werner, R. N., and Yawalkar, N.

Published
2015
Full Text
View/download PDF

36. Les mutations ADAR1 entraînant un psoriasis sévère dépendant de l’interféron de type I : un biomarqueur en vue d’une médecine de précision

Author

Assan, F., Izmiryan, A., Tragin, M., Fremond, M.L., Di Domizio, J., Akroun, F., Mahé, E., Sbidian, E., Guégan, S., Aubin, F., Chang, M., Satishkumar, D., Costanzo, A., Bourrat, E., Seneschal, J., Sohier, P., Battistella, M., Guerrera, C., Bole, C., Nitschke, P., Crow, Y., Gilliet, M., Gudjonsson, J.E., and Bachelez, H.

Abstract

Peu de modèles monogéniques de psoriasis en plaques (PsO) ont été identifiés. Nous rapportons le rôle pathogène de variants perte de fonction du gène adénosine déaminase agissant sur l’ARN1 (ADAR1) dans une population de malades atteints de PsO.

Published
2024
Full Text
View/download PDF

37. Survenue de cancers cutanés chez les patients atteints de psoriasis exposés aux traitements conventionnels, à la photothérapie ou à une biothérapie : analyse d’une cohorte prospective de patients psoriasiques recevant des traitements systémiques

Author

Bergqvist, C., Curmin, R., Zehou, O., Basset-Seguin, N., Pham-Ledard, A., Madji, K., Klising, E., Younes, I., Mahé, E., Bachelez, H., Dupuy, A., Joly, P., Richard, M.A., Sbidian, E., Beneton, N., Jullien, D., Viguier, M., Paul, C., Beylot-Barry, M., Chosidow, O., and Tubach, F.

Published
2023
Full Text
View/download PDF

45. Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study

Author

Richard, M.‐a., Paul, C., de Pouvourville, G., Jullien, D., Mahe, E., Bachelez, H., Seneschal, J., Misery, L., Aubert, R., Reguiai, Z., Shourick, J., Taieb, C., Joly, P., Ezzedine, K., Essec Business School, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Victor Dupouy, Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB), Laboratoire sur les interactions Epithéliums Neurones (LIEN), Université de Brest (UBO), Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Toulouse [Toulouse], European Market Maintenance Assessment [Fontenay-sous-Bois] (EMMA ), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Mondor], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
vitiligo, Mesures adjuvantes, MESH: Interferon-gamma, Associated measures, MESH: Long-Term Care, MESH: Skin, interferon-γ, MESH: Melanocytes, MESH: Physicians, MESH: Surveys and Questionnaires, skin and connective tissue diseases, Prescriber, Systemic glucocorticoid therapy, MESH: Humans, MESH: Long Term Adverse Effects, MESH: Middle Aged, integumentary system, Corticothérapies systémiques, pathogenesis, MESH: Polypharmacy, cytotoxic CD8+ T cells, targeted therapies, MESH: Keratinocytes, MESH: Male, Prescripteur, MESH: Practice Patterns, Physicians', MESH: Specialization, MESH: Vitiligo, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; Vitiligo is the most common depigmenting disorder affecting 0.1%-2% of the population worldwide. The characteristic white patches result from the selective loss of melanocytes. Sustained recent efforts have resulted in a detailed understanding of the genetic architecture of vitiligo. About 80% of vitiligo risk is attributable to genetic factors; and the rest (20%) is attributable to the environment. Over the past decade, substantial progress has been made in our understanding of the pathogenesis of vitiligo which is now clearly classified as an autoimmune disease. Melanocytes from patients with vitiligo are more susceptible to oxidative stress which begets the release of exosomes and inflammatory cytokines that will lead to activation of the innate immune response and subsequently to adaptive immune response through activation of autoreactive cytotoxic CD8+ T cells. These produce interferon-γ (IFN-γ) which promotes disease progression through IFN-γ-induced chemokine secretion from surrounding keratinocytes to further recruit T cells to the skin through a positive feedback loop. CD8 tissue-resident memory T cells are in turn responsible for long-term maintenance and potential relapse of vitiligo in human patients through cytokine-mediated recruitment of T cells from the circulation. This review summarizes the current knowledge on vitiligo and attempt to give an overview of the future in vitiligo treatment.

Published
2021

46. Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohortPSOBIOTEQ.

Author

Curmin, R., Guillo, S., De Rycke, Y., Bachelez, H., Beylot‐Barry, M., Beneton, N., Chosidow, O., Dupuy, A., Joly, P., Jullien, D., Richard, M.A., Viguier, M., Sbidian, E., Paul, C., Mahé, E., and Tubach, F.

Subjects
BIOLOGICALS, PSORIASIS, TUMOR necrosis factors, COMPETING risks, SURVIVAL analysis (Biometry)
Abstract

Background: Biologics are the cornerstone of treatment of patients with moderate‐to‐severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. Objectives: The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents. Methods: We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate‐to‐severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra‐class – i.e. within the same therapeutic class ‐ vs. inter‐class) in patients switching from a TNF‐alpha inhibitor using multivariate logistic regression. Results: A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF‐alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL‐17 inhibitor. Patients switching from a first‐line TNF‐alpha inhibitor before 2016 were more likely to switch to another TNF‐alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF‐alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab. Conclusion: This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL‐17 inhibitors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Palmoplantar pustulosis and acrodermatitis continua of Hallopeau: demographic and clinical comparative study in a large multicentre cohort.

Author

Assan, F., Husson, B., Hegazy, S., Seneschal, J., Aubin, F., Mahé, E., Jullien, D., Sbidian, E., D'Incan, M., Conrad, C., Brenaut, E., Girard, C., Richard, M.A., Bachelez, H., and Viguier, M.

Subjects
AGE of onset, BODY mass index, RHEUMATISM, COMPARATIVE studies, INDIVIDUALIZED medicine
Abstract

Background: Acral pustular disease within the pustular psoriasis/psoriasis‐like spectrum mainly includes palmoplantar pustulosis (PPP) and acrodermatitis continua of Hallopeau (ACH). Scarce data argue for a distinction between these two entities, but no study has compared the clinical and epidemiologic characteristics of ACH and PPP. Objectives: We aimed to perform a comparative description of the epidemiological and clinical characteristics of PPP and ACH in a multicentre retrospective cohort. Methods: In this multicentre national retrospective cohort study, we compared the epidemiological characteristics, comorbidities and psoriasis characteristics of patients with PPP and ACH. Results: A total of 234 patients were included: 203 (87%) with PPP, 18 (8%) with ACH and 13 (6%) with both, according to 2017 ERASPEN criteria. As compared with ACH, PPP was associated with female sex, smoking activity and higher median BMI (P = 0.01, P = 0.02 and P = 0.05 respectively). A family background of psoriasis was more frequent in PPP than ACH. Age of onset of palmoplantar disease was similar between PPP and ACH patients, median age 44 and 48 years respectively. Peripheral joint inflammatory involvement was the only rheumatic disease associated with ACH. The association with another psoriasis type was similar in PPP and ACH (57.6% and 61.1% respectively). Conclusion: Our study confirms in a large PPP cohort the predominance of females and a high prevalence of smoking and elevated body mass index but also shows an association of these features in PPP as compared with ACH. In addition, it highlights peripheral arthritis as the only arthritis endotype associated with ACH. Increased knowledge of the immunogenetic backgrounds underlying these two entities is warranted to better stratify pustular psoriasis or psoriasis‐like entities for precision medicine. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort

Author

Beylot‐Barry, M., primary, Seneschal, J., additional, Tran, D., additional, Bachelez, H., additional, Beneton, N., additional, Dupuy, A., additional, Joly, P., additional, Jullien, D., additional, Mahé, E., additional, Paul, C., additional, Richard, M.‐A., additional, Sbidian, E., additional, Viguier, M., additional, Chosidow, O., additional, and Tubach, F., additional

Published
2021
Full Text
View/download PDF

49. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type : a cross-sectional patient survey

Author

Mahil, S. K., Yates, M., Langan, S. M., Yiu, Z. Z.N., Tsakok, T., Dand, N., Mason, K. J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Bruce, I. N., Capon, F., Contreras, C. R., Cope, A. P., De La Cruz, C., Di Meglio, P., Gisondi, P., Hyrich, K., Jullien, D., Lambert, J., Marzo-Ortega, H., McInnes, I., Naldi, L., Norton, S., Puig, L., Sengupta, R., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Griffiths, C. E.M., Barker, J. N., Brown, M. A., Galloway, J. B., Smith, C. H., other, and, Mahil, S. K., Yates, M., Langan, S. M., Yiu, Z. Z.N., Tsakok, T., Dand, N., Mason, K. J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Bruce, I. N., Capon, F., Contreras, C. R., Cope, A. P., De La Cruz, C., Di Meglio, P., Gisondi, P., Hyrich, K., Jullien, D., Lambert, J., Marzo-Ortega, H., McInnes, I., Naldi, L., Norton, S., Puig, L., Sengupta, R., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Griffiths, C. E.M., Barker, J. N., Brown, M. A., Galloway, J. B., Smith, C. H., and other, and

Abstract

Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. Objectives: We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. Methods: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. Results: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term ‘shielding’). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35–1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23–1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05–1·24), obesity (OR 1·37, 95% CI 1·23–1·54), comorbidity burden (OR 1·43, 95% CI 1·15–1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27–1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36–1·80). Modest differences in the proportion shielding were observed across nations. Conclusions: Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contr

Published
2021

50. Describing the burden of the COVID-19 pandemic in people with psoriasis : findings from a global cross-sectional study

Author

Mahil, S. K., Yates, Mark, Yiu, Z. Z.N., Langan, S. M., Tsakok, T., Dand, N., Mason, Kayleigh J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Capon, F., Contreras, C. R., De La Cruz, C., Di Meglio, P., Gisondi, P., Jullien, D., Lambert, J., Naldi, L., Norton, S., Puig, L., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Brown, M. A., Galloway, J. B., Griffiths, C. M., Barker, J. N., Smith, C. H., other, and, Mahil, S. K., Yates, Mark, Yiu, Z. Z.N., Langan, S. M., Tsakok, T., Dand, N., Mason, Kayleigh J., McAteer, H., Meynell, F., Coker, B., Vincent, A., Urmston, D., Vesty, A., Kelly, J., Lancelot, C., Moorhead, L., Bachelez, H., Capon, F., Contreras, C. R., De La Cruz, C., Di Meglio, P., Gisondi, P., Jullien, D., Lambert, J., Naldi, L., Norton, S., Puig, L., Spuls, P., Torres, T., Warren, R. B., Waweru, H., Weinman, J., Brown, M. A., Galloway, J. B., Griffiths, C. M., Barker, J. N., Smith, C. H., and other, and

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results